Our investment case

To deliver value to our stakeholders as a responsible corporate citizen that provides high quality, affordable medicines globally.

Global footprint with weighting towards emerging markets

2 088 in emerging countries

304in developed countries

Medicines supplied to more than 130 emerging and over 25 developed countries

Diverse product portfolio with strong brand equity

176 medicines on the Essential Medicines List¹

547 prescription branded and over-the-counter (“OTC”) medicines

Our wide product portfolio of trusted brands spanning most therapeutic areas creates meaningful diversification

¹ World Health Organization Essential Medicines List

Strategically relevant manufacturing capital

Widely accredited and compliant API and FDF manufacturing sites with an increasing focus on complex sterile capacities

Responsible corporate citizen and trusted partner

Consistent inclusion in the
FTSE/JSE Responsible
Investment
Index
since 2016

Constituent
member of the
FTSE4Good
Index

Committed management team, strongly aligned with shareholders’ interests

Entrepreneurial, decentralised management teams with local expertise